Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Invivyd Inc (IVVD)

Invivyd Inc (IVVD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 492,079
  • Shares Outstanding, K 282,804
  • Annual Sales, $ 53,430 K
  • Annual Income, $ -52,490 K
  • EBIT $ -56 M
  • EBITDA $ -53 M
  • 60-Month Beta 0.73
  • Price/Sales 9.05
  • Price/Cash Flow N/A
  • Price/Book 1.65

Options Overview Details

View History
  • Implied Volatility 112.78% (-5.94%)
  • Historical Volatility 116.98%
  • IV Percentile 3%
  • IV Rank 2.07%
  • IV High 1,010.24% on 06/27/25
  • IV Low 93.77% on 01/08/26
  • Expected Move (DTE 25) 0.2975 (17.45%)
  • Put/Call Vol Ratio 50.19
  • Today's Volume 819
  • Volume Avg (30-Day) 601
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 21,473
  • Open Int (30-Day) 20,376
  • Expected Range 1.4075 to 2.0025

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.08
  • Number of Estimates 1
  • High Estimate $-0.08
  • Low Estimate $-0.08
  • Prior Year $-0.14
  • Growth Rate Est. (year over year) +42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1700 +47.01%
on 03/30/26
1.8000 -4.44%
on 04/17/26
+0.3400 (+24.64%)
since 03/20/26
3-Month
1.1700 +47.01%
on 03/30/26
2.3050 -25.38%
on 01/22/26
-0.5200 (-23.21%)
since 01/20/26
52-Week
0.4830 +256.11%
on 08/21/25
3.0699 -43.97%
on 11/17/25
+1.2100 (+237.25%)
since 04/17/25

Most Recent Stories

More News
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Elia to speak at the premier gathering of policy makers, industry leaders, and health experts between 11:30 AM ET – 12:00 PM ET on April 21 Event to be live streamed between 9:00 AM – 1:00 PM ET...

IVVD : 1.6950 (-2.59%)
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accumulated to date (~ 50% of study progress) can already provide sufficient statistical power to support...

IVVD : 1.6950 (-2.59%)
Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health

National education campaign aims to educate Americans about antibodies and their role in immune health Campaign centerpiece, AntibodiesforAnyBody.com , offers an interactive immune health wellness...

IVVD : 1.6950 (-2.59%)
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., April 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on April 1, 2026, Invivyd granted 16 newly hired non-executive employees options to purchase an...

IVVD : 1.6950 (-2.59%)
Invivyd Announces Presentation at the World Vaccine Congress Washington

Chief Scientific Officer, Robert Allen, Ph.D., presented as part of the “Antibodies for Infectious Disease Workshop” at the World Vaccine Congress Washington Presentation titled “Developing mAb...

IVVD : 1.6950 (-2.59%)
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Achieved Q4 2025 PEMGARDA ® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter 2025 year-end cash and cash equivalents of...

IVVD : 1.6950 (-2.59%)
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women’s Hospital,...

IVVD : 1.6950 (-2.59%)
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced...

IVVD : 1.6950 (-2.59%)
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an...

IVVD : 1.6950 (-2.59%)
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

“A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was published...

IVVD : 1.6950 (-2.59%)

Business Summary

INVIVYD INC. is a biopharmaceutical company. It involved in developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. INVIVYD INC., formerly known as Adagio Therapeutics, is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 1.8800
2nd Resistance Point 1.8400
1st Resistance Point 1.7900
Last Price 1.6950
1st Support Level 1.7000
2nd Support Level 1.6600
3rd Support Level 1.6100

See More

52-Week High 3.0699
Fibonacci 61.8% 2.0817
Fibonacci 50% 1.7765
Last Price 1.6950
Fibonacci 38.2% 1.4712
52-Week Low 0.4830

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.